65
Senti Biosciences, Inc. raises $37.6M under Reg D
Company raise · Raising · Offering $120.6M · Sold $37.6M · SOUTH SAN FRANCISCO, CA · filed 2024-12-19
Placement agent engaged
47
Senti Biosciences Holdings, Inc. raises $10M under Reg D
Company raise · Raising · SOUTH SAN FRANCISCO, CA · Form D filed 2026-06-04
$10M+ raise
How this compares
- Among 1,632 fund launches filed from CA in the same window it is larger than 65%; the CA median is $19M.
- No earlier fund launch by this sponsor appears on EDGAR.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
Raise progress
| Filed | Form | Sold | Investors | Change |
|---|---|---|---|---|
| 2024-12-19 | D | $37.6M | 15 | |
| 2026-06-04 | D | $10M | 1 | −$27.6M |
Amount sold and investor count as restated on each of the issuer's Form D filings. A rise since the previous filing is capital closed in between.
Senti Biosciences on EDGAR
Earlier and related filings by the same issuer and sponsor.
People on the filing
| Frances D. Schulz | Director |
| James J. Collins | Director |
| Jay J. Cross | Executive Officer |
| Brenda D. Cooperstone | Director |
| Timothy Lu | Executive Officer, Director |
| Bryan J. Baum | Director |
| Kanya J. Rajangam | Executive Officer |
| Feng J. Hsiung | Director |
| Donald D. Tang | Director |
| Edward Mathers | Director |
[email protected] · observed Work emails for the people on the filing, where the firm publishes or patterns them, labelled by confidence — subscribers
Signed by Timothy Lu, Chief Executive Officer.
Why now — by persona
Relevant to: Executive & technical recruiting, B2B software & services sales, Commercial banking / treasury, D&O and management-liability insurance, Outsourced accounting / CFO.
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans.